Inhaled and Intranasal Products Contract Service Providers Market, 2030 - What is the Impact of COVID-19 Outbreak on the Market
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The 'Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 - 2030' report features an extensive study of the current market landscape and future opportunities for the contract service providers focused on drugs and drug delivery systems. It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in this domain.
Targeting the delivery of drugs directly into the lungs is deemed to be the most effective way to ensure optimal therapeutic benefits while treating pulmonary disorders. In addition, this route of administration has also been shown to be effective for drugs intended to treat a variety of other conditions, including various metabolic (460+ million adults estimated to be living with diabetes) , hormonal, autoimmune, infectious diseases/disorders and mental health conditions (260 million individuals estimated to be suffering from depression and around 50 million have epilepsy, worldwide).
As a result, innovators in the pharmaceutical industry are engaged in efforts to develop the means to formulate and administer pharmacological interventions via inhalation and/or the intranasal route. Since 2019, the FDA has approved multiple inhaled and intranasal drug products, namely TOSYMRAT (migraine), NUMBRINOT (local anesthetic), GIMOTIT (diabetic gastroparesis), VALTOCO (epilepsy), NAYZILAM (epilepsy), DUAKLIR PRESSAIR (COPD), PROAIR DIGIHALERT (asthma and COPD), AIRDUO DIGIHALERT (asthma), SPRAVATO (depression).
Presently, several players are attempting to develop inhalable versions of different classes of drugs. In such endeavors, reformulating complex therapeutic molecules (such as biologics), novel drug classes (such as nanoparticle based medicine) and those intended for systemic delivery, present unique challenges.Further, the inhaled route of delivery itself has always been associated with several challenges, mostly related to ensuring the drug to its intended target.
These concerns are further compounded by multiple physiological barriers, such as mucus hypersecretion/thickening, narrowing/collapse of airways, fibrosis and poor blood circulation. In order to navigate through the aforementioned challenges, innovators prefer to rely on specialty service providers with expertise in inhaled and intranasal nasal medicine.
Such players, given their experience and niche expertise, enable innovator companies to not only expedite product development and production timelines, but also offer cost saving opportunities as well. Further, such service providers generally have the necessary infrastructure to scale-up operations in order to meet the evolving needs of a business across different stages of product development.
Given the anticipated growth in demand for inhaled and intranasal drug products, the specialty contract services market catering to this segment of the pharmaceutical industry, is anticipated to witness substantial growth in the coming years.
Key Questions Answered
Who are the leading contract service providers offering inhalable and intranasal products related services, across the world?
In which regions are majority of the inhaled and intranasal product related manufacturing facilities located?
What percentage of inhaled and intranasal manufacturing operations are outsourced?
Which partnership models are commonly adopted by stakeholders in this industry?
What is the impact of COVID-19 outbreak on inhaled and intranasal product services market?
What is the current, global demand for inhaled and intranasal products?
How is the current and future market opportunity likely to be distributed across key market segments?
Companies Mentioned
3M
3P innovation
Actelion Pharmaceuticals
Aerami Therapeutics (formerly Dance Biopharm)
Aerosol Research and Engineering Laboratories
Akums Drugs & Pharmaceuticals
Alcami
Alpic Biotech
Altaris Capital Partners
Altimmune
Amneal Pharmaceuticals
Aptar Pharma
Arch Biopartners
Arcturus Therapeutics
ASM Aerosol-Service
Aspen Pharmacare
AstraZeneca
Atossa Therapeutics
Aurohealth
Basic Pharma
Battelle
Bespak
Beximco Pharmaceuticals
BioCare Group
Biofilms Research Center for Biointerfaces, Malmo University
Boehringer Ingelheim
Breath Therapeutics
Capsugel
Carclo Technical Plastics
Catalent
CF PharmTech
Charles River Laboratories
Chemic Laboratories
Chiesi Farmaceutici
Chromcore Lifesciences
Cirrus Pharmaceuticals
COC Farmaceutici
Colep
Confab
Consort Medical
Contract Pharmaceuticals
Creative Biolabs
Circassia
CrystecPharma
Curida
CytoAgents
Dalton Pharma Services
DFE Pharma
Doctor Pack
Dorizoe Lifesciences
DPT Laboratories
Dr. Reddy's Laboratories
DRK Pharma Solutions
Dwarkesh Pharmaceuticals
EKG Life Science Solutions
Elfin Drugs
Emmace Consulting
Ennaid Therapeutics
Ethris
Eurofins
Evoke Pharma
Evonik
Experic
Farbe Firma
FAMAR
Focus Inhalation
Forefront Medical Technology
Forest Laboratories
Genentech
Gerresheimer
Getron Pharmaceuticals
Gilead Sciences
GlaxoSmithKline
Global Pharma
Hikma Pharmaceuticals
Horizon Pharmaceuticals
Hovione
Humanigen
Iconovo
IIT Research Institute (IITRI)
Impopharma
Importfab
Inhalexpert
InhaTarget Therapeutics
Insmed
Intas Pharmaceuticals
Intertek
Invion
iPharma
ITC Farma
J Pharmaceuticals
Jabil
Jagotec
Janssen Pharmaceuticals
Johnson & Johnson
Kiel University
Kindeva Drug Delivery
King's College London
Kymos Pharma Services
Labiana Pharmaceuticals
Lamda Laboratories
Lannet Technologies
LEAX Group
Lepharm
Life Vision Healthcare
Lindal Group
Liquidia Technologies
Lomapharm
Lonza
Lovelace Biomedical
Lxir Medilabs (A unit of SMM Life Sciences)
M2M Pharmaceuticals
Macter International
Malmo University
MannKind
Mapaex
Maya Biotech
McMaster University
Medicair Bioscience Laboratories
Medicilon
Medlab Pharmaceuticals
MedPharm
Menarini Group
Merck
Micro-Sphere
MidasCare
Mipharm
MMG Healthcare
Moderna Therapeutics
Molex
Medicon Valley Inhalation Consortium (MVIC)
Mylan
Nanologica
Nanopharm
Napp Pharmaceuticals
Nelipak Healthcare Packaging
Nelson Laboratories
Nemera
Nephron Pharmaceuticals
Neurelis
Neurimmune
Newtec Pro Manufacturing
Next Breath
Nipro
Nitto Medic
Nivon Specialties
Noble
Novartis
One Pharma
Orion
Ote Pharma
Optinose
Paragon Nordic
PARI Pharma
PCI Pharma Services
Penta Arzneimittel
Pfizer
Pharma Stulln
Pharma Tech
PharmaCielo
Pharmaserve
Pharmaterials
PHAST (Acquired by Eurofins)
Phillips-Medisize
Pine Lake Laboratories
Polyphor
PPD Laboratories
Probiotec
Propeller Health
Proveris Scientific
Pulmatrix
PulmoFlow
Pursuit Pharma
Pushkar Pharma
Quotient Sciences
Recipharm
Renaissance Pharmaceuticals
Roche
Rommelag
Rubicon Research
S.R.Chemicals and Pharmaceuticals
SAFE Pharmaceutical
Salvat
Sandoz
Sanofi
Sciarra Laboratories
Seikagaku
Sentiss Pharma
Servier Pharmaceuticals
SHL Group
Simpler Consulting
SkyePharma
Smithers
Spicona
Stabicon Life Sciences
Stevanato Group
Summit Biosciences
Sunovion
Sunovion Pharmaceuticals
Synerlab
Takeda
Teva Pharmaceuticals
The Indian Pharmaceutical Association
The Ritedose Corporation
Theravance Biopharma
Tinuum
Toxikon
Trillium Health Care Products
UCB Pharma
Ultratech India
United Therapeutics
University of Birmingham
University of Copenhagen
University of Cyprus
University of Florida
University of Turku
Bausch Health (formerly Valeant Pharmaceuticals)
Vectura
ViralClear Pharmaceuticals (A subsidiary of BioSig Technologies)
Vinventions
Vivimed
West Coast Pharmaceutical
Westmed Medical Group
For more information about this report visit https://www.researchandmarkets.com/r/onk748
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900